Goldman Sachs
MDGL icon

Goldman Sachs’s Madrigal Pharmaceuticals MDGL Stock Holding History

Goldman Sachs’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$4.24M – 6176
2024
Q3 		$4.24M Hold
20,000
– – ﹤0.01% 3490
2024
Q2 		$5.6M Buy
+20,000
New +$4.76M ﹤0.01% 3046
2021
Q1 		– Sell
-12,600
Closed -$1.4M – 6235
2020
Q4 		$1.4M Sell
12,600
-10,000
-44% -$1.22M ﹤0.01% 3976
2020
Q3 		$2.68M Buy
+22,600
New +$2.45M ﹤0.01% 3358

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs's MDGL Position: Q2 2026 in Review

Goldman Sachs reduced its Madrigal Pharmaceuticals (MDGL) stake by 11% in Q2 2026, selling an estimated $15.9M and leaving 246,280 shares worth $132M. The position accounts for 0.01% of the portfolio, ranked #1019.

Goldman Sachs first reported a position in MDGL in Q2 2013 and has held it in 50 quarters since. The position peaked at $178M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Goldman Sachs held 246,280 shares of Madrigal Pharmaceuticals worth $132M as of Q2 2026.
  • Goldman Sachs sold 31,091 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $15.9M.
  • Madrigal Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1019 holding.
  • Goldman Sachs first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
  • Goldman Sachs's Madrigal Pharmaceuticals position peaked at $178M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.